People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other Technology, Other, Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Guavus Inc | — | Other Technology | Series C | $172.9M | $1.6B | 2011 |
| Crossbar, Inc. | — | Other | Series B | $133.5M | $37.4M | 2023 |
| Niron Magnetics, Inc. | — | Other Technology | Series C | $106.0M | $994.5M | 2016 |
| Mateon Therapeutics Inc | — | Biotechnology | Series B | $45.3M | $1.1M | 2020 |
| Insightra Medical, Inc. | — | Other Health Care | Series A | $20.0M | $100.9M | 2014 |
| Lightwire Inc | — | Other Technology | Series A | $14.0M | $388.4M | 2011 |
| Marius Pharmaceuticals, LLC | — | Pharmaceuticals | Series B | $11.6M | $129.3M | 2019 |
| Zyme Solutions Inc | — | Other Technology | Series A | $9.0M | $83.2M | 2009 |
| Adama Materials, Inc. | — | Other Technology | Seed | $4.3M | $28.9M | 2013 |
| DYYNO Inc | — | Other Technology | Seed | $2.9M | $98.4M | 2011 |
Amit Shah at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Amit Shah on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Saurabh Srivastava | 2 | 4 |
| Francis Thibodeau | 2 | 2 |
| Somu Subramaniam | 1 | 17 |
| Dharmesh Thakker | 1 | 11 |
| Mark Davis | 1 | 11 |
| David Seldin | 1 | 11 |
| Michael Liang | 1 | 9 |
| Wen Hsieh | 1 | 9 |
| Tim Wilson | 1 | 7 |
| Yatin Mundkur | 1 | 7 |
| Jose Suarez | 1 | 7 |
| Jay Shah | 1 | 6 |
| David Michael | 1 | 6 |
| Amit Parikh | 1 | 6 |
| Vuong Trieu | 1 | 5 |
| Anthony Maida | 1 | 5 |
| Bobby W. Sandage, Jr. | 1 | 5 |
| Lei Yang | 1 | 4 |
| Daniel Omstead | 1 | 4 |
| Anne Dorman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.